Fulgent Genetics, Inc. (FLGT) Misses Q2 EPS by 14c ; Offers Guidance

Fulgent Genetics, Inc. (NASDAQ: FLGT) reported Q2 EPS of ($0.58), $0.14 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $85.4 million versus the consensus estimate of $91.77 million.

GUIDANCE:

Fulgent Genetics, Inc. sees FY2026 EPS of ($2.22)-($2.35), versus the consensus of ($1.55). Fulgent Genetics, Inc. sees FY2026 revenue of $330-340 million, versus the consensus of $352.2 million.

For earnings history and earnings-related data on Fulgent Genetics, Inc. (FLGT) click here.

You May Also Be Interested In

• Corning (GLW) files for up to $2B offering of common shares
• Northrop Grumman wins two U.S. defense contracts worth $38.7m
• 1844 Resources closes private placement raising $947,650